At the time of writing, Beta Bionics Inc [BBNX] stock is trading at $18.84, up 0.69%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BBNX shares have gain 10.50% over the last week, with a monthly amount glided 12.21%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Beta Bionics Inc [NASDAQ: BBNX] stock has seen the most recent analyst activity on June 16, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $26. Previously, Lake Street started tracking the stock with Buy rating on June 12, 2025, and set its price target to $30. On May 30, 2025, Wolfe Research initiated with a Outperform rating and assigned a price target of $20 on the stock. Goldman started tracking the stock assigning a Neutral rating and suggested a price target of $16 on May 30, 2025. Stifel initiated its recommendation with a Buy and recommended $25 as its price target on February 24, 2025. Piper Sandler started tracking with a Overweight rating for this stock on February 24, 2025, and assigned it a price target of $26. In a note dated February 24, 2025, Leerink Partners initiated an Outperform rating and provided a target price of $28 on this stock.
For the past year, the stock price of Beta Bionics Inc fluctuated between $8.89 and $24.50. Currently, Wall Street analysts expect the stock to reach $17 within the next 12 months. Beta Bionics Inc [NASDAQ: BBNX] shares were valued at $18.84 at the most recent close of the market. An investor can expect a potential drop of -9.77% based on the average BBNX price forecast.
Analyzing the BBNX fundamentals
According to Beta Bionics Inc [NASDAQ:BBNX], the company’s sales were 78.02M for trailing twelve months, which represents an 54.45% jump. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at -0.8%, Pretax Profit Margin comes in at -0.94%, and Net Profit Margin reading is -0.94%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.41 and Total Capital is -0.2. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.20 points at the first support level, and at 17.56 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.40, and for the 2nd resistance point, it is at 19.96.
Ratios To Look Out For
It is important to note that Beta Bionics Inc [NASDAQ:BBNX] has a current ratio of 14.68. Further, the Quick Ratio stands at 13.79, while the Cash Ratio is 1.8. Considering the valuation of this stock, the price to sales ratio is 10.50, the price to book ratio is 2.71.
Transactions by insiders
Recent insider trading involved Feider Stephen, Chief Financial Officer, that happened on Aug 22 ’25 when 4413.0 shares were sold. Officer, Feider Stephen completed a deal on Aug 22 ’25 to buy 4413.0 shares. Meanwhile, Chief Commercial Officer Hopman Mark sold 16158.0 shares on Aug 19 ’25.
